Novel Toll-Like Receptor Inhibitors for Treatment of Inflammatory Disease

Dr. Katzenellenbogen from the University of Illinois at Urbana-Champaign has developed a novel class of inhibitors capable of inhibiting Toll-like Receptor signaling. These compounds will allow treatment of inflammatory diseases such as sepsis. Currently there are no TLR inhibitors on the market and this novel set of compounds show higher affinity than currently published compounds. In addition to high specificity for TLRs these compounds are also able to be derivatized for specificity to specific classes of TLRs.